Skip to content
value.today

Inflammatix, Inc.

🇺🇸 Burlingame, California, USABiotechnologyFounded 2016
Total raised
$134 M
2 rounds on record
Latest round
$102 M
Mar 2021
First round on record
Jan 2020
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Inflammatix, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$102 MNo. 2$50 to $250 million

Inflammatix, Inc.: Raise no. 2, Mar 2021

Investors in this round

8 investors had bought by the notice of Mar 24, 2021: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$102 M of $102 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Timothy Sweeney · Executive Officer, Director
  • David Persing · Director
  • Justin Kao · Director
  • Kenneth Bahk · Director
  • Michael Rubin · Director
  • Steven Tablak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Timothy Sweeney, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 24, 2021. Read the notice at the SEC.

equitySEC
Jan 2020$32 MNo. 1$10 to $50 million

Inflammatix, Inc.: Raise no. 1, Jan 2020

Investors in this round

6 investors had bought by the notice of Feb 3, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$32 M of $32 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan Romanowsky · Executive Officer
  • Timothy Sweeney · Executive Officer, Director
  • David Persing · Director
  • Kenneth Bahk · Director
  • Michael Rubin · Director
  • Steven Tablak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Timothy Sweeney, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 3, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Inflammatix, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2021

That is all the official record says: Inflammatix, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Inflammatix, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Inflammatix, Inc.
NameRoleNamed in
Timothy SweeneyExecutive officerMar 2021
Jonathan RomanowskyExecutive officerFeb 2020
David PersingDirectorMar 2021
Justin KaoDirectorMar 2021
Kenneth BahkDirectorMar 2021
Michael RubinDirectorMar 2021
Steven TablakDirectorMar 2021
Timothy SweeneyDirectorMar 2021